Chemotherapy-induced cardiotoxicity: Current practice and prospects of prophylaxis

European Journal of Heart Failure

Volumn 4, Issue 3, 2002, Pages 235-242

  Gharib, M I ^a   Burnett, A K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anthracyclines; Cardiomyopathy; Cardiotoxicity; Chemotherapy; Cyclophosphamide; Heart

Indexed keywords

ANTHRACYCLINE; ATRIAL NATRIURETIC FACTOR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ENDOTHELIN 1; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; MITOMYCIN; MITOXANTRONE; RAZOXANE; TROPONIN;

ANGIOCARDIOGRAPHY; CARDIOMYOPATHY; CARDIOTOXICITY; DIAGNOSTIC IMAGING; DISEASE MARKER; HEART EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE NECROSIS; HEART SCINTISCANNING; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL MARKERS; HEART; HEART DISEASES; HUMANS; RISK FACTORS;

EID: 0036623690     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(01)00201-X     Document Type: Review

References (81)

1. Tan C, Tasaka H, Kou-Ping Y et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease: clinical evaluation with special reference to childhood leukemia. Cancer 1967;20:333-53.
2. Hitchcock-Bryan S, Jeal GRC. The impact of induction anthracyclines on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1986;14:211-5.
3. Ettinghausen SE, Bonow RO, Palmeri ST et al. Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg 1986;121:1445-51.
4. Frishman WH, Sung HM, Yee HC et al. Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer 1997;21:301-60.
5. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 1978;62:955-61.
6. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302.
7. VonHoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
8. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
9. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
10. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15.
11. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study. Pediatr Cardiol 1999;20:252-63.
12. Lipshultz SE, Lipsitz SR, Mone SM et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
13. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25:72-85.
14. Legha SS, Benjamin RS, Mackay B et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9.
15. Torti FM, Bristow MR, Howes AE et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983;99:745-9.
16. Weiss AJ, Metter GE, Fletcher WS, Wilson WL, Grage TB, Ramirez G. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976;60:813-22.
17. Weiss AJ, Manthel RW. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 1977;40:2046-52.
18. Chlebowski RT, Paroly WS, Pugh RP et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980;64:47-51.
19. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-52.
20. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 1993;21:477-9.
21. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978;88:168-75.
22. Praga C, Beretta G, Vigo PL et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979;63:827-34.
23. Pihkala J, Saarinen UM, Lundstrom U et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996;32A:97-103.
24. Boucek RJ, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA. Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 1999;31:1435-46.
25. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study. J Clin Oncol 2001;19:191-6.
26. Friedman MA, Bozdech MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA 1978;240:1603-6.
27. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med 1978;65:823-32.
28. Lewis AB, Crouse VL, Evans W, Takahashi M, Siegel SE. Recovery of left ventricular function following discontinuation of anthracycline chemotherapy in children. Pediatrics 1981;68:67-72.
29. Moreb JS, Oblon DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer 1992;70:2637-41.
30. Schwartz RG, McKenzie WB, Alexander J et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109-18.
31. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709-18.
32. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106:1048-56.
33. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 1987;9:184-8.
34. Hausdorf G, Morf G, Beron G et al. Long term doxorubicin cardiotoxicity in childhood: non-invasive evaluation of the contractile state and diastolic filling. Br Heart J 1988;60:309-15.
35. Marchandise B, Schroeder E, Bosly A et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92-8.
36. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992;20:62-9.
37. Ganz WI, Sridhar KS, Forness TJ. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am J Clin Oncol 1993;16:109-12.
38. Ewer MS, Ali MK, Gibbs HR et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol 1994;33:645-9.
39. Cottin Y, Touzery C, Coudert B et al. Impairment of diastolic function during short-term anthracycline chemotherapy. Br Heart J 1995;73:61-4.
40. Schmitt K, Tulzer G, Merl M et al. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters. Eur J Pediatr 1995;154:201-4.
41. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 1986;55:274-82.
42. Billingham MEBM. Evaluation of anthracycline cardiotoxicity:predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 1984;3:71-6.
43. Pegelow CH, Popper RW, de Wit SA, King OY, Wilbur JR. Endomyocardial biopsy to monitor anthracycline therapy in children. J Clin Oncol 1984;2:443-6.
44. Isner JM, Ferrans VJ, Cohen SR et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am J Cardiol 1983;51:1167-74.
45. Neri B, DeScalzi M, De LV, Gemelli MT, Ghezzi P, Pacini P. Preliminary study on behaviour of atrial natriuretic factor in anthracycline-related cardiac toxicity. Int J Clin Pharmacol Res 1991;11:75-81.
46. Bauch M, Ester A, Kimura B, Victorica BE, Kedar A, Phillips MI. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992;69:1492-7.
47. Tikanoja T, Riikonen P, Perkkio M, Helenius T. Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediatr Oncol 1998;31:73-8.
48. Suzuki T, Hayashi D, Yamazaki T et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136:362-3.
49. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999;62:135-41.
50. Yamashita J, Ogawa M, Nomura K. Plasma endothelin-1 and doxorubicin cardiotoxicity. N Engl J Med 1994;331:1528-9.
51. Yamashita J, Ogawa M, Shirakusa T. Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer 1995;62:542-7.
52. Lipshultz SE, Rifai N, Sallan SE et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997;96:2641-8.
53. Missov E, Calzolari C, Davy JM, Leclercq F, Rossi M, Pau B. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997;8:537-41.
54. Ganzina F. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983;10:1-22.
55. Jain KK, Casper ES, Geller NL et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985;3:818-26.
56. Brambilla C, Rossi A, Bonfante V et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986;70:261-6.
57. Villani F, Galimberti M, Comazzi R, Crippa F. Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin). Eur J Cancer Clin Oncol 1989;25:13-8.
58. Lopez M, Contegiacomo A, Vici P et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1989;64:2431-6.
59. Speyer JL, Green MD, Kramer E et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-52.
60. Speyer JL, Green MD, Zeleniuch-Jacquotte A et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992;10:117-27.
61. Hochster H, Liebes L, Wadler S et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992;84:1725-30.
62. Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-32.
63. Hensley ML, Schuchter LM, Lindley C et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-55.
64. Henderson BM, Dougherty WJ, James VC, Tilley LP, Noble JF. Safety assessment of a new anticancer compound, mitoxantrone in beagle dogs: comparison with doxorubicin.; I. Clinical observations. Cancer Treat Rep 1982;66:1139-43.
65. Sparano BM, Gordon G, Hall C, Iatropoulos MJ, Noble JF. Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology. Cancer Treat Rep 1982;66:1145-58.
66. Mather FJ, Simon RM, Clark GM, Von Hoff DD. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 1987;71:609-13.
67. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985;3:123-32.
68. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-8.
69. Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant 1993;12:169-72.
70. Gardner SF, Lazarus HM, Bednarczyk EM et al. High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. Bone Marrow Transplant 1993;12:139-44.
71. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141:758-63.
72. Steinherz LJ, Steinherz PG, Mangiacasale D et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol 1981;9:417-22.
73. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-8.
74. Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31-6.
75. Buzdar AU, Legha SS, Tashima CK et al. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep 1978;62:1005-8.
76. Villani F, Comazzi R, Lacaita G et al. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med Oncol Tumor Pharmacother 1985;2:93-7.
77. Verweij J, Funke-Kupper AJ, Teule GJ, Pinedo HM. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother 1988;5:159-63.
78. Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982;68:505-10.
79. Patel B, Kloner RA, Ensley J, Al Sarraf M, Kish J, Wynne J. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294:238-43.
80. Rezkalla S, Kloner RA, Ensley J et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989;7:509-14.
81. De Forni M, Malet-Martino MC, Jaillais P et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10:1795-801.